FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US
FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.
Search
FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*
FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*
Help in all situations in life
Boehringer Ingelheim focuses on the wellbeing of its employees – and is therefore also a "Global Top Employer 2023".
IASLC NACLC 2020: Boehringer Ingelheim Presents New Data | BI US
BI announces new data for GILOTRIF®, affirming its activity in SCC of the lung with findings presented at the IASLC 2020. View ISI, PI and Med Guide.
Cardiologists at the Heart of Cardio-Renal-Metabolic Care | Boehringer Ingelheim US
Cardiologists at the Heart of Cardio-Renal-Metabolic Care
Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US
Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.
Jardiance® (empagliflozin) Lessened Risk of Heart Failure | Boehringer Ingelheim US
The EMPRISE real-world study shows JARDIANCE saw a decreased risk of hospitalization for heart failure. View ISI, PI and Med Guide.
Our evolved employer value proposition
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
Express Scripts Adds BI Products to Roster | BI US
Read more on Express Scripts adding the Spiriva Respimat, Spiriva Handihaler and Stiolto Respimat to their commercial national preferred formulary.
Are combination therapies the answer to battling KRAS cancers?
Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
Boehringer welcomes 2023 Gold Report
Boehringer welcomes 2023 GOLD Report Positioning LAMA/LABA as preferred treatment
Disability Inclusion at Work: Top Score | Boehringer Ingelheim US
Click here to read more on Boehringer Ingelheim receiving a 100 score with Disability:IN’s “Best Place to Work for Disability Inclusion” for the 5th year!
Partnering Days
Partnering Days
Management Rotation | Academic Programs
Management Rotation Program
Adopting shelter pets: Employees make a difference at work and home
Adopting shelter pets: Employees make a difference at work and home
Life forward - Boehringer Ingelheim unveils its evolved company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
Recognized as an inclusive workplace for the fifth time
Recognized as an Inclusive Workplace for the Fifth Time
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
Shelter Revamps Make for Strong Bonds, More Adoptions
Shelter Revamps Make for Strong Bonds, More Adoptions
KDIGO’s 2024 Updated Guidelines Re-Emphasize Commitment to Comprehensive Testing for CKD
Mohamed Eid shares his thoughts on the updated KDIGO clinical practice guidelines, published in 2024, and the need for guidelines-directed care for CKD.
Innovating for our business
We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.
Application Platform Data privacy statement
(Application Platform) Data Privacy Statement | Boehringer Ingelheim Careers and Job Opportunities
We’re looking for SAP developers to join our Global IT Department
Are you looking to take the next step in your career? Our global IT department has new SAP developer positions available!
Information Technology
IT
R&D - Transforming tomorrow
Manami Tsutsumi, Senior Associate Director in Research & Development describes what it is like working on the cutting edge of pharmaceutical development.